The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act

October 08, 2024 06:31 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascicularis) under the Endangered Species Act ("ESA"). 


The decision caps a review by USFWS in which the Service found the petition did not present credible information to support impacts to LTM populations or the species as a whole due to potential threats, either separately or cumulatively, such that the species may warrant listing.

Long-tailed macaques are used extensively throughout the world in biomedical research given their close approximation to human beings. Six of the 25 most used prescription drugs were developed with the help of long-tailed macaques.1 Research with long-tailed macaques has been crucial for advances in regenerative medicine,2 immunology,3 cancer,4 vaccine development,5 and pharmacology.6 The National Institutes for Health (NIH) recently published a review confirming the importance of LTMs in conducting biomedical research.

The USFWS decision follows a recent decision by the International Union for Conservation of Nature (IUCN)'s decision to reconsider the "Endangered" designation of LTM in response to a petition from the National Association for Biomedical Research (NABR) challenging the listing decision by IUCN.7 The IUCN directed authors that had conducted a status review (Hansen et al. 2022) to reevaluate their assessment to address scientific issues raised by NABR in its petition. 

NABR's petition showed the 2022 review by Hansen et. al., which the IUCN used as the basis for its decision to uplist the long-tailed macaque's status, misrepresented existing scientific data. A separate petition filed by Dr. Hank Jenkins, which remains pending before the IUCN, asserts that the Hansen et al. (2022) authors possess conflicts of interest that require further investigation by the IUCN.   

"NABR is pleased that the USFWS has declined to accept the petition filed by PETA and other advocacy groups based upon its consideration of the best available scientific information," said Matthew R. Bailey, president of NABR. "Available scientific information clearly shows that this species is not at risk and does not warrant a further status review. NABR looks forward to working with USFWS to ensure the integrity of its scientific processes."

The conservation status of long-tailed macaque and PETA's involvement in government programs was recently the subject of a U.S. House of Representatives Oversight Committee hearing in September 2024. Witnesses at this hearing testified that PETA and other animal advocacy groups had improperly attempted to influence government investigations of private parties and foreign governments for political reasons.

More information regarding the NABR petition is available online at www.nabr.org

About the National Association for Biomedical Research
Founded in 1979, the National Association for Biomedical Research (NABR) is the only 501(c)(6) nonprofit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at www.nabr.org.

1 FBR's Role of LTMs in Research Fact Sheet 01-2024 FINAL, available online at https://fbr-cms-bucket.s3.us-west-1.amazonaws.com/FBR_s_Role_of_LT_Ms_in_Research_Fact_Sheet_01_2024_FINAL_802d17fd7d.pdf?updated_at=2024-02-26T16:44:17.000Z 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848615/#:~:text=Non%2Dhuman%20primates%20play%20a,organs%20affected%20by%20degenerative%20diseases. regenerative medicine
3 https://www.nature.com/articles/s41577-018-0005-7 immunology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808758/#:~:text=Furthermore%2C%20NHP%20naturally%20develop%20cancers,and%20patients%20with%20human%20cancer. cancer research/therapies
5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886327/ behavioral pharmacology
6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402317/ COVID 19 vaccine development
7 See Hilborn, R., & Smith, D. R. (2023). Is the long–tailed macaque at risk of extinction? American Journal of Primatology, e23590. https://doi.org/10.1002/ajp.23590

Contact: Eva Maciejewski
[email protected]
(202) 967-8305

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.